drugset
drugset / Trial / NCT04056962

Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma

NCT04056962 ↗

Phase 2 Unknown 50 enrolled West China Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

Timeline

Start
2019-09-01
Primary completion
2024-08-30
Completion
2024-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.03 % Topical
Subject Tacrolimus Small molecule 0.1 % Topical

Indications

blood vessel neoplasm